Search

Search Constraints

You searched for: Author/Creator Kolitz, Jonathan E.

Search Results

1. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Issue 3 (23rd February 2020)

2. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia. Issue 1 (28th June 2012)

3. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. (1st August 2016)

4. Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Issue 15 (12th May 2016)

5. Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Issue 2 (15th September 2014)

6. Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Issue 2 (15th September 2014)

7. Primary Low-Grade B-Cell Lymphoma of Skull With Translocation Between Immunoglobulin and Interferon Regulatory Factor 4 Genes. (May 2020)

9. Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808. Issue 7 (31st December 2013)

10. Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808. Issue 7 (31st December 2013)